We are pleased to introduce two new members to NewAge’s Board of Directors, Dr. Anthony Green and Ms. Lisa Wyman. Both individuals have extensive backgrounds in improving manufacturing processes, management roles, and the biopharmaceutical industry.
Our Board of Directors consists of a group of experienced businesspeople with diverse credentials. As a whole, the Board holds a supervisory role and oversees NewAge’s corporate activities, assists with its long-term goals, and puts shareholders – which in NewAge’s case are its dedicated employee-owners – first.
Dr. Anthony Green is Chief Scientific Officer for an organization involved with the Pennsylvania Department of Community and Economic Development. Dr. Green has over 30 years’ experience in the biotechnology industry involving small, emerging companies focused on the development and commercialization of cutting-edge technologies in immunodiagnostics, monoclonal antibodies, and gene transfer technologies. Dr. Green earned his Bachelor of Science degree in Immunology from Brown University and his Ph.D. in Microbiology and Immunology from Temple University School of Medicine.
Ms. Lisa Wyman is a biopharmaceutical executive with more than 20 years’ experience in the areas of biologics, small molecule technology, and medical devices. Her background includes positions involving drug development and manufacturing, supply chain, quality and regulatory compliance, and engineering, and she specializes in business strategy, employee engagement, corporate governance, and business continuity planning. Ms. Wyman’s Bachelor of Science degree in Biology was earned at Ithaca College, and her Master of Science Degree in Engineering Management is from Tufts University.
